RT Journal Article
SR Electronic
T1 Cell-Mediated and Humoral Immune Response to 2-Dose SARS-CoV2 mRNA vaccination in Immunocompromised patient population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260921
DO 10.1101/2021.07.21.21260921
A1 Muthukumar Ramanathan
A1 Kanagavel Murugesan
A1 Lu M. Yang
A1 Cristina Costales
A1 Philip L. Bulterys
A1 Joseph Schroers-Martin
A1 Ash A. Alizadeh
A1 Scott D. Boyd
A1 Janice M. Brown
A1 Kari C. Nadeau
A1 Sruti S. Nadimpalli
A1 Aileen X. Wang
A1 Stephan Busque
A1 Benjamin A. Pinsky
A1 Niaz Banaei
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.21.21260921.abstract
AB Characterization of cell-mediated and humoral immune responses to SARS-CoV2 mRNA vaccine has implications for protective immunity in immunocompromised patients. However, studies have demonstrated poor humoral response to SARS-CoV2 mRNA vaccine in immunocompromised patients and data on cellular immune response are currently lacking. Here we compared immune response after 2-dose vaccination in 100 immunocompromised patients (solid organ transplant recipients, hematologic malignancy, autoimmune condition, and primary immunodeficiency) and 16 immunocompetent healthy healthcare workers. We find that 100% (CI=80.6-100%) of immunocompetent individuals show positive cell-mediated and humoral immune response post vaccination while only 50% (CI=40.4-59.6%) of immunocompromised patients show humoral immune response and 69% (CI=59.4-77.2%) have a positive cell-mediated immune response. 21% of immunocompromised patients have no humoral immune response or cell-mediated immune response and thus are likely vulnerable to SARS-CoV2 infection. Monitoring of immune response in immunocompromised populations, particularly in high-risk immunocompromised patients (solid organ transplant recipients, patients with severe autoimmunity, and those ≥50 years), with clinical IGRA and serological assay after vaccination may identify patients who may benefit from revaccination or prophylactic monoclonal antibody therapy to prevent COVID-19 in this patient populationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was utilized for this analysis. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University Institutional Review Board (IRB-60171 and IRB-57519)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article. De-identified data of this study could be shared upon request.